For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer expanded its cost-cutting plans and posted first-quarter profit above estimates, despite a decline in sales driven by falling revenue from its Covid pill, according to CNBC. The company ...

Pfizer (NYSE:PFE) surged about 3% on Tuesday ... Management reaffirmed its full-year 2025 outlook, noting that the forecast does not currently include any potential impact related to future ...

Pfizer reported weaker first-quarter results on Tuesday, with revenue falling short of Wall Street estimates, but earnings beating expectations. The US drugmaker reaffirmed its full-year 2025 ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, "which we are unable to predict at this time." ...

Pfizer ( PFE) reported mixed first quarter earnings Tuesday, as the company struggles to gain investor interest in its ...

Pfizer on Tuesday reaffirmed its outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker looks to turn around its business postpandemic. The company forecast ...

"We are currently trending towards the upper end of our 2025 adjusted diluted EPS guidance range." Pfizer (PFE) Chief Executive Albert Bourla stuck to the company's profit and revenue forecast for ...

Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped ... Pfizer did not revise its outlook. The company maintained its full-year 2025 outlook ...